natgillin/translations-raw huggingface dataset:
Somatropin Biopartners 2 mg powder for prolonged-release suspension for injection somatropin
Somatropin Biopartners 2 mg prašek za suspenzijo za injiciranje s podaljšanim sproščanjem somatropin s.c. za odrasle
Each vial of powder delivers 2 mg somatropin; each vial of solvent contains 1.5 mL liquid.
Ena viala praška dostavi 2 mg somatropina; ena viala vehikla vsebuje 1,5 ml tekočine.
Each vial of powder delivers 10 mg somatropin; each vial of solvent contains 1.5 mL liquid.
Ena viala praška dostavi 10 mg somatropina; ena viala vehikla vsebuje 1,5 ml tekočine.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS VIAL OF SOLVENT
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Each vial of powder delivers 4 mg somatropin; each vial of solvent contains 1.5 mL liquid.
Ena viala praška dostavi 4 mg somatropina; ena viala vehikla vsebuje 1,5 ml tekočine.
Powder: Vial (type I glass) closed with a rubber stopper (butyl) and a pink flip-off cap (aluminium and plastic).
Prašek: Viala (steklo tipa I), zaprta z gumijastim zamaškom (butil) in rožnato prekrivno zaporko (aluminij in plastika).
INFORMATION IN BRAILLE Somatropin Biopartners 2 mg
ZUNANJA OVOJNINA SOMATROPIN BIOPARTNERS 2 MG
Talk to your doctor before using Somatropin Biopartners if you: - have a hereditary disease called Prader-Willi syndrome: You should not be treated with this medicine unless you also have a lack of growth hormone; - have had a tumour: Your doctor will examine you frequently to ensure that the tumour has not come back; - have symptoms like severe and recurrent headache, visual changes, nausea and/or vomiting which may be due to increased pressure in the skull during growth hormone treatment; - suffer from an organic growth hormone deficiency (lack of growth hormone due to damage to the pituitary gland or the part of the brain called the hypothalamus) or decreased secretion of
Pred začetkom uporabe zdravila Somatropin Biopartners se posvetujte s svojim zdravnikom, če: - imate dedno bolezen, imenovano Prader-Willijev sindrom: s tem zdravilom se ne smete zdraviti, če nimate hkrati tudi pomanjkanja rastnega hormona.
Somatropin Biopartners 7 mg powder for prolonged-release suspension for injection somatropin
Somatropin Biopartners 7 mg prašek za suspenzijo za injiciranje s podaljšanim sproščanjem somatropin s.c. za odrasle
INFORMATION IN BRAILLE Somatropin Biopartners 10 mg
ZUNANJA OVOJNINA SOMATROPIN BIOPARTNERS 10 MG
Somatropin Biopartners 7 mg powder and solvent for prolonged-release suspension for injection Somatropin
Somatropin Biopartners 7 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem somatropin za odrasle
Powder: Vial (type I glass) closed with a rubber stopper (butyl) and a yellow flip-off cap (aluminium and plastic).
Prašek: Viala (steklo tipa I), zaprta z gumijastim zamaškom (butil) in rumeno prekrivno zaporko (aluminij in plastika).
Somatropin Biopartners 2 mg powder and solvent for prolonged-release suspension for injection somatropin
Somatropin Biopartners 2 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem somatropin za odrasle
Powder: Vial (type I glass) closed with a rubber stopper (butyl) and a green flip-off cap (aluminium and plastic).
Prašek: Viala (steklo tipa I), zaprta z gumijastim zamaškom (butil) in zeleno prekrivno zaporko (aluminij in plastika).
Somatropin Biopartners 4 mg powder and solvent prolonged-release for suspension for injection somatropin
Somatropin Biopartners 4 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem somatropin za odrasle
Solvent: Vial (Type I glass) closed with a rubber stopper (butyl) and a flip-off cap (aluminium and plastic).
Vehikel: Viala (steklo tipa I), zaprta z gumijastim zamaškom (butil) in prekrivno zaporko (aluminij in plastika).
Powder: Vial (type I glass) closed with a rubber stopper (butyl) and a light-green flip-off cap (aluminium and plastic).
Prašek: Viala (steklo tipa I), zaprta z gumijastim zamaškom (butil) in svetlozeleno prekrivno zaporko (aluminij in plastika).
Gently pinch the skin that has been cleaned, to make a fold.
Očiščeno kožo nežno stisnite v gubo.
Pack size of 4 vials of powder and 4 vials of solvent.
Velikost pakiranja 4 viale praška in 4 viale vehikla.
Remove the needle guard.
- Navodilo shranite.
Respiratory, thoracic and mediastinal disorders Common: Epistaxis
Bolezni dihal, prsnega koša in mediastinalnega prostora pogosti: krvavitev iz nosu
6.3 Shelf life
6.3 Seznam pomožnih snovi
Further information on Doptelet can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/doptelet.
Nadaljnje informacije o zdravilu Doptelet so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/doptelet.
It is available as 20-mg tablets.
Na voljo je v obliki 20-miligramskih tablet.
Treatment with Doptelet should start at least 10 days before the procedure.
Zdravljenje z zdravilom Doptelet se mora začeti vsaj deset dni pred postopkom.
The European Medicines Agency decided that Doptelet's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zaključila, da so koristi zdravila Doptelet večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Other information about Doptelet
Druge informacije o zdravilu Doptelet
What measures are being taken to ensure the safe and effective use of Doptelet?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Doptelet?
As for all medicines, data on the use of Doptelet are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Doptelet stalno spremljajo.
What is Doptelet and what is it used for?
Kaj je zdravilo Doptelet in za kaj se uporablja?
The medicine is for use in patients having an invasive procedure (a medical procedure that involves cutting into or puncturing the skin or inserting instruments into the body).
Zdravilo se uporablja pri bolnikih ob invazivnem postopku (medicinskem posegu, ki vključuje vrez ali punkcijo kože ali vstavitev instrumentov v telo).
What benefits of Doptelet have been shown in studies?
Kakšne koristi zdravila Doptelet so se pokazale v študijah?
Why is Doptelet authorised in the EU?
Zakaj je bilo zdravilo Doptelet odobreno v EU?
A blood test on the day of the procedure is necessary to ensure that the platelet count is adequate and not unexpectedly high.
Na dan postopka je treba opraviti krvne preiskave za zagotovitev, da je število trombocitov ustrezno in ni nepričakovano previsoko.
An overview of Doptelet and why it is authorised in the EU
Pregled zdravila Doptelet in zakaj je odobreno v EU
Doptelet is a medicine used to prevent excessive bleeding in adults with thrombocytopenia due to long-standing liver disease.
Doptelet je zdravilo, ki se uporablja za preprečevanje čezmerne krvavitve pri odraslih s trombocitopenijo zaradi dolgotrajne bolezni jeter.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Doptelet have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Doptelet upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
For more information about using Doptelet, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Doptelet glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Any unwanted effects during treatment with Doptelet were thought to result from patients' medical condition and the nature of the invasive procedure for which it was used.
Neželeni učinki, ki so se pojavili med zdravljenjem z zdravilom Doptelet, naj bi bili posledica zdravstvenega stanja bolnikov in narave invazivnega postopka, pri katerem je bilo to zdravilo uporabljeno.
Two main studies in 435 patients with low levels of platelets due to long-standing liver disease found Doptelet effective at increasing platelet levels before an invasive procedure.
V dveh glavnih študijah pri 435 bolnikih z nizkimi ravnmi trombocitov zaradi dolgotrajne bolezni jeter se je zdravilo Doptelet izkazalo za učinkovito pri povečanju ravni trombocitov pred invazivnim postopkom.
The dose is 2 or 3 tablets (depending on the platelet count at the start of treatment), daily for 5 days.
Odmerek znaša dve ali tri tablete (odvisno od števila trombocitov ob začetku zdravljenja) vsak dan pet dni zapored.
Side effects reported with Doptelet are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Doptelet, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Among patients with more severe thrombocytopenia, 67% of those given Doptelet 60 mg daily did not require a transfusion or rescue procedure compared with 29% of those who received placebo.
Pri bolnikih z resnejšo trombocitopenijo 67 % tistih, ki so prejemali zdravilo Doptelet v odmerku 60 mg na dan, ni potrebovalo transfuzije ali postopka reševanja, v primerjavi z 29 % tistih, ki so prejemali placebo.
Patients with thrombocytopenia have reduced number of platelets (components in the blood that help it to clot), which can cause excessive bleeding.
Bolniki s trombocitopenijo imajo zmanjšano število trombocitov (sestavin v krvi, ki pomagajo pri strjevanju krvi), kar lahko povzroči čezmerno krvavitev.
The most common side effect with Doptelet (which may affect up to 1 in 10 people) is tiredness.
Najpogostejši neželeni učinek zdravila Doptelet (ki se lahko pojavi pri največ 1 od 10 bolnikov) je utrujenost.
What are the risks associated with Doptelet?
Kakšna tveganja so povezana z zdravilom Doptelet ?
In these studies, 88% of patients who received Doptelet 40 mg daily did not require a transfusion or rescue procedure compared with 36% of patients who were given placebo (a dummy treatment).
V teh študijah 88 % bolnikov, ki so prejemali zdravilo Doptelet v odmerku 40 mg na dan, ni potrebovalo transfuzije ali postopkov reševanja, v primerjavi s 36 % bolnikov, ki so prejemali placebo (zdravilo brez učinkovine).
The platelet count increased in patients treated with Doptelet.
Število trombocitov se je pri bolnikih, zdravljenih z zdravilom Doptelet, povečalo.
The active substance in Doptelet, avatrombopag, attaches to the same receptors as thrombopoietin, helping to increase the platelet count.
Učinkovina v zdravilu Doptelet , avatrombopag, se veže na iste receptorje kot trombopoetin in pomaga povečati število trombocitov.
For the full list of side effects and restrictions with Doptelet, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Doptelet glejte navodilo za uporabo.
Doptelet contains the active substance avatrombopag.
Zdravilo Doptelet vsebuje učinkovino avatrombopag.
How is Doptelet used?
Kako se zdravilo Doptelet uporablja?
Doptelet can only be obtained with a prescription.
Predpisovanje in izdaja zdravila Doptelet je le na recept.
In the body, a hormone called thrombopoietin stimulates the production of platelets by attaching to receptors (targets) in the bone marrow.
Nastajanje trombocitov v telesu spodbuja hormon trombopoetin, tako da se veže na receptorje (prijemališča) v kostnem mozgu.
The main measure of effectiveness was the number of patients who did not require a transfusion of platelets or other treatment ('rescue procedure') to prevent excessive bleeding after starting Doptelet treatment and for up to 7 days after their invasive procedure.
trombocitov ali drugačne vrste zdravljenja („postopek reševanja“), da bi preprečili čezmerno krvavitev po začetku zdravljenja z zdravilom Doptelet in do sedem dni po invazivnem postopku.
Studies have found that Doptelet reduced the need for platelet transfusions or other rescue treatments to prevent excessive bleeding before an invasive procedure and for up to 7 days afterward.
Študije so pokazale, da zdravilo Doptelet pred invazivnim postopkom in še sedem dni po njem zmanjša potrebo po transfuziji trombocitov ali drugih postopkih reševanja za preprečevanje čezmerne krvavitve.
How does Doptelet work?
Kako zdravilo Doptelet deluje?
10 bottles
10 stekleničk
It is ineffective against Enterobacteriaceae.
Ni učinkovit proti enterobakterijam.
53000 LAVAL France
53000 LAVAL Francija
Treatment durations beyond three weeks
Trajanje zdravljenja, daljše od treh tednov
PRODIVET, Comércio de Produtos Químicos, Farmacêuticos e Cosméticos, SA
Portugalska PRODIVET, Comércio de Produtos Químicos, Farmacêuticos e Cosméticos, SA
Lilly Portugal - Produtos Farmaceuticos, Lda.
Portugalska Lilly Portugal - Produtos Farmaceuticos, Lda.
949 01 Nitra Slovakia
949 01 Nitra Slovaška
2665-507 Venda do Pinheiro Portugal
2665-507 Venda do Pinheiro Portugalska
It may be administered by oral or parenteral routes.
Uporablja se lahko peroralno ali parenteralno.
92521 Neuilly sur Seine cedex France
92521 Neuilly sur Seine cedex Francija
Ceva Saúde Animal Produtos Farmacêuticos e Imunológicos, Lda.
Portugalska Ceva Saúde Animal Produtos Farmacêuticos e Imunológicos, Lda.
LABORATORIOS MAYMO VIA AUGUSTA 302 08017 BARCELONA Spain
LABORATORIOS MAYMO VIA AUGUSTA 302 08017 BARCELONA Španija
REPRESENTAGROREPRESENTAÇOES LDA Estrada da Lapa 1
Portugalska REPRESENTAGROREPRESENTAÇOES LDA Estrada da Lapa 1
Resistance is caused by point mutations of 23S rDNA.
Odpornost povzročajo točkovne mutacije rDNA 23S.
Dr. Franje Tuđmana 3 10431, Sveta Nedelja Croatia
Dr. Franje Tuđmana 3 10431, Sveta Nedelja Hrvaška
Tylosin is not used in human medicine.
Tilozin se ne uporablja pri človeku.
Oral tylosin has had widespread use in pig farming in many EU Member States for decades to treat and prevent disease and before entry into force of Regulation (EC) No 1831/2003, as a growth promoter.
Peroralni tilozin se že desetletja obsežno uporablja v prašičjereji v mnogih državah članicah EU za zdravljenje in preprečevanje bolezni, pred veljavnostjo Uredbe (ES) št. 1831/2003 pa se je uporabljal tudi kot promotor rasti.
To limit the selection pressure for bacteria unnecessary use should be avoided.
Da bi omejili selektivni pritisk za bakterije, se je treba izogibati nepotrebni uporabi.
Kalinovica, 10436 Rakov Potok Croatia
Kalinovica, 10436 Rakov Potok Hrvaška
16 Aleia Vazrajdane str., ap.42 Bulgaria
16 Aleia Vazrajdane str., ap.42 Bolgarija
3, Vyt and Hommez (2006) 4, MARAN (2008)
SVARM (2002-2009) 3, Vyt in Hommez (2006) 4, MARAN (2008)
As macrolides are critically important antimicrobials for pigs, unnecessary exposure leading to further resistance in target animal pathogens would be a serious risk to animal health.
Ker so makrolidi kritično pomembni antibiotiki pri prašičih, bi nepotrebna izpostavljenost, ki bi povzročila dodatno odpornost v patogenih pri ciljnih živalskih vrstah, predstavljala resno tveganje za zdravje živali.
LABORATOIRES BIOVE 3 RUE DE LORRAINE 62510 ARQUES France
LABORATOIRES BIOVE 3 RUE DE LORRAINE 62510 ARQUES Francija
17170 Amer (Girona) Spain
17170 Amer (Girona) Španija
Crida Pharm SRL str. Intrarea Vagonetului nr.2, bl.101, ap.47, parter, sector 6 Bucharest
Romunija Crida Pharm SRL str. Intrarea Vagonetului nr.2, bl.101, ap.47, parter, sector 6 Bucharest
For similar reasons recommendations to reduce the initial dose for an extended treatment period are not acceptable.
Zaradi podobnih razlogov priporočilo za zmanjšanje začetnega odmerka za namene dolgotrajnega zdravljenja ni sprejemljivo.
These products are effective medicines for the treatment of several diseases such as respiratory disease and ileitis/porcine intestinal adenopathy (caused by Lawsonia intracellularis).
Ta zdravila so učinkovita za zdravljenje več bolezni, kot so bolezni dihal in ileitis/prašičja črevesna adenopatija (ki jo povzroča Lawsonia intracellularis).
Tylosin and its phosphate and tartrate salts are used in food producing species for the treatment of conditions caused by sensitive organisms.
Tilozin in njegove soli (fosfat ter tartrat) se uporabljajo pri vrstah, namenjenih proizvodnji hrane, za zdravljenje bolezni, ki jih povzročajo občutljivi organizmi.
Sintofarm Via P. Togliatti, 5 Guastalla (RE) Italy
Sintofarm Via P. Togliatti, 5 Guastalla (RE) Italija
In contrast, premix formulations authorised for the treatment and prevention of ileitis (caused by Lawsonia intracellularis) most often recommend treatment for not longer than up to three weeks.
V nasprotju je pri formulacijah predmešanic, odobrenih za zdravljenje in preprečevanje ileitisa (ki ga povzroča Lawsonia intracellularis), pogosto priporočeno zdravljenje, ki ni daljše od treh tednov.
Tylosin is a macrolide antibiotic which is produced by Streptomyces fradiae.
Tilozin je makrolidni antibiotik, ki ga proizvaja Streptomyces fradiae.
A similar treatment strategy is recommended for tylosin premix formulation for the treatment of swine dysentery where it is mentioned that treatment can be continued ‘until the end of risk', ‘as long as necessary' or ‘until slaughter'.
Podobna strategija zdravljenja je priporočena za formulacije predmešanice z tilozinom pri zdravljenju prašičje dizenterije, pri čemer je omenjeno, da se lahko zdravljenje nadaljuje „do konca tveganja“, „dokler je potrebno“ ali „do zakola“.
The general acceptance of the fact that antimicrobial treatment needs always to be combined with appropriate management and sanitary measures on the farm, to prevent the further spread of any particular microbe and thus reduce the risk for new clinical cases, makes it difficult to defend a need for very long treatment periods.
Zaradi splošno sprejetega dejstva, da je treba antimikrobno zdravljenje vedno kombinirati z ustrezno obravnavo ter sanitarnimi ukrepi na kmetiji, da bi preprečili nadaljnje širjenje posameznih mikrobov in tako zmanjšali tveganje novih kliničnih primerov, je težko zagovarjati potrebo po zelo dolgem zdravljenju.
Extended exposure of tylosin to pigs is related to risk for development of antimicrobial resistance.
Velika izpostavljenost tilozina prašičem je povezana s tveganjem razvoja antimikrobne odpornosti.
The cause for the high resistance rate can be found in the mechanisms governing the development of non-horizontal transferable resistance.
Vzrok za velik delež odpornosti je lahko mehanizem, ki nadzira razvoj nehorizontalno prenosljive odpornosti.
SC Delos Impex 96 SRLStr Horia, Closca si Crisan, Otopeni judetul Ilfov
Romunija SC Delos Impex 96 SRLStr Horia, Closca si Crisan, Otopeni judetul Ilfov
It is active mostly against Gram-positive bacteria and mycoplasmas.
Večinoma deluje proti grampozitivnim bakterijam in mikoplazmam.
Oral tylosin is regarded as an effective medicine against several diseases in pigs.
Peroralni tilozin je učinkovito zdravilo proti več boleznim pri prašičih.
The potential risk for resistance development is evident through the current resistance situation of B. hyodysenteriae.
Morebitno tveganje za razvoj odpornosti so pokazali s trenutno situacijo glede odpornosti B. hyodysenteriae.
With regard to respiratory disease in pigs, tylosin premix formulations are currently often authorised for treatment using a higher dose for the first two to three weeks of treatment followed by a lower dose (typically 40% of the initial dose) for an extended period of time, often stated as the ‘whole risk period'.
Za bolezni dihal pri prašičih so formulacije predmešanic s tilozinom trenutno pogosto odobrene za zdravljenje z večjim odmerkom prva dva do tri tedne zdravljenja, ki mu sledi dolgotrajno zdravljenja z manjšim odmerkom (navadno 40 % začetnega odmerka), pogosto imenovano „celotno obdobje tveganja“.
Priestley Road Basingstoke, RG24 9NL United Kingdom
Priestley Road Basingstoke, RG24 9NL Združeno kraljestvo
The CVMP was asked to conclude on whether the duration of treatment with veterinary medicinal products containing tylosin beyond three weeks is justified and whether these products are still effective against swine dysentery caused by B. hyodysenteriae.
Odbor CVMP so prosili, naj potrdi, ali je trajanje zdravljenja z zdravili za uporabo v veterinarski medicini, ki vsebujejo tilozin, ki je daljše od treh tednov, upravičeno in ali so ta zdravila še učinkovita proti prašičji dizenteriji, ki jo povzroča B. hyodysenteriae.
Applicant/Marketing authorisation holder
Predlagatelj/imetnik dovoljenja za promet z zdravilom
Biovet JSC 39 Petar Rakov Str 4550 Peshtera Bulgaria
Biovet JSC 39 Petar Rakov Str 4550 Peshtera Bolgarija
In this situation it is not to be expected that scientifically well founded justifications for treatment durations can be obtained from the different marketing authorisation holders for different indications for pigs.
V takih okoliščinah ni pričakovati, da bi lahko znanstveno dobro utemeljene dokaze za trajanje zdravljenja pri različnih indikacijah pri prašičih pridobili od različnih imetnikov dovoljenj za promet z zdravili.
Тиловет Форте водоразтворими гранули за свине
Тиловет Форте водоразтворими гранули за свине svinje
Germany aniMedica GmbH Im Südfeld 9
Nemčija aniMedica GmbH Im Südfeld 9
Since for B. hyodysenteriae the rRNA operon exists in a single copy one single base mutation is sufficient to achieve macrolide resistant clones (Zuerner and Stanton (1994)
Ker je operon rRNA za B. hyodysenteriae prisoten v obliki ene kopije, je mutacija ene same baze zadostna za ustvarjanje klonov, odpornih proti makrolidom (Zuerner in Stanton (1994)
Thus, it cannot be expected that data concurring with current
Torej ni mogoče pričakovati, da bodo na voljo podatki, ki bi jih bilo mogoče uporabiti skupaj s trenutnimi potrebami in ki bi omogočili
D-49377 Vechta
D-49377 Vechta Nemčija
AniMed Service AG Liebochstrasse 9 8143 Dobl Austria
AniMed Service AG Liebochstrasse 9 8143 Dobl Avstrija
1, the CVMP recommendations on macrolides state that ‘there might be a need to review certain SPCs to reduce the approved treatment duration in cases where it is found unnecessarily long in relation to the severity of the disease'.
1, priporočila odbora CVMP glede makrolidov navajajo, da „bo morda treba pregledati nekatere povzetke glavnih značilnosti zdravil, da se skrajša odobreno trajanje zdravljenja, kadar ni potrebno, da je zdravljenje dolgo glede na resnost bolezni.“.
D-48308 Senden-Bösensell Germany
D-48308 Senden-Bösensell Nemčija
The published scientific reports regarding the resistance situation for B. hyodysenteriae provide a discouraging picture, where tylosin resistance today is close to complete in many areas of the European Union.
Objavljena znanstvena poročila o stanju odpornosti B. hyodysenteriae kažejo neugodno sliko, saj je danes odpornost proti tilozinu na mnogih območjih v Evropski uniji skoraj popolna.
Replace, where applicable, treatment recommendations which are extended beyond 3 weeks, or where no treatment duration recommendation is given, with the following statement: Treatment duration should not exceed 3 weeks.
Če je primerno, zamenjajte priporočilo glede zdravljenja, daljšega od treh tednov, ali odsotnost priporočila glede trajanja zdravljenja z naslednjim stavkom: Zdravljenje ne sme trajati več kot 3 tedne.
Delete, where applicable, any recommendation to reduce the dose after an initial treatment period with a higher dose.
Če je primerno, izbrišite morebitno priporočilo za zmanjšanje odmerka po začetnem obdobju zdravljenja z večjim odmerkom.
A recent report from Spain (Alvarez et al. (2013))
Nedavno poročilo iz Španije (Alvarez in sod.
th international conference on colonic spirochaetal infections in animals and humans in the United Kingdom in September 2013, it was mentioned in a key note that: “tylosin has been rendered totally ineffective through widespread use for in-feed medication over the years” (Thomson (2013))
Skladno s temi opažanji so med 6. mednarodno konferenco o okužbah debelega črevesa s spirohetami pri živalih in ljudeh v Združenem kraljestvu septembra 2013 v ključnem sporočilu omenili, da: „je zaradi obsežne uporabe kot zdravilo za dajanje v krmo z leti tilozin postal popolnoma neučinkovit“ (Thomson (2013))